Effects of 2-Chlorodeoxyadenosine and Gold Sodium Thiomalate on Human bcl-2 Gene Expression

References

• Aringer M., Wintersberger W., Steiner C. W., Kiener H., Presteri E., Jaeger U., Smolen J. S., Graninger W. B. High levels of bcl-2 protein in circulating T lymphocytes, but not B lymphocytes, of patients with systemic lupus erythematosus. Arthritis Rheum. 1994; 37: 1423
   PubMed Web of Science ®Google Scholar
• Bettens F., Kristensen F., Walker C., Schwulera U., Bonnard G. D., de Week A. L. Lymphokine regulation of activated (G,) lymphocytes. II. Glucocorticoid and antiTac-induced inhibition of human T lymphocyte proliferation. J. Immunol. 1984; 132: 261
   PubMed Web of Science ®Google Scholar
• Carrera C. J., Terai C., Curd J. G., Piro L. D., Beutler E., Carson D. A. Potent toxicity of 2-chloro-deoxyadenosine toward human monocytes in vitro and in vivo. J. Clin. Invest. 1990; 86: 1480
   PubMed Web of Science ®Google Scholar
• Carrera C. J., Weisman M., Amox D., Clason M., Carson D. A. Oral 2- chlorodeoxyadenosine treatment for rheumatoid arthritis. Arthritis Rheum 1994; 37(No 9, (suppl.))S421
   Google Scholar
• Carson D. A., Wasson D. B., Esparza L. M., Carrera C. J., Kipps T. J., Cottam H. B. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2-arabino- fluoro-2-deoxyadenosine. Proc. Natl. Acad. Sci. 1992; 89: 2970
   PubMed Web of Science ®Google Scholar
• Dimopoulos M. A., Kantarjian H., Estey E., O'Brien S., DelaSalle K., Keating M. J., Freirich E. J., Alexanian R. Treatment of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. Ann. Intern. Med. 1993; 118: 195
   PubMed Web of Science ®Google Scholar
• Eibschutz B., Baird S. M., Weisman M. H., Amox D. G., Spellman M., Piacquadio D., Carrera C. J., Carson D. A. Oral 2-chlorodeoxyadenosine in psoriatic arthritis. Arthritis Rheum. 1995; 38: 1604
   PubMed Web of Science ®Google Scholar
• Firestein G. S., Yeo M., Zvaifler N. J. Apoptosis in rheumatoid arthritis synovium. J. Clin. Invest. 1995; 96: 1631
   PubMed Web of Science ®Google Scholar
• Gorski A., Grieb P., Makula J., Stepien-Sopniewska B., Mrowiec T., Nowaczyk M. 2-cnloro-2-deoxyadenosine: a novel immunosuppressive agent. Transplantation 1993a; 56: 1253
   PubMed Web of Science ®Google Scholar
• Gorski A., Grieb P., Korczak-Kowalska G., Wierzbicki P., Stepien-Sopniewska B., Mrowiec T. Cladribine (2-chloro-deoxyadenosine, CDA): an inhibitor of human B and T cell activation in vitro. Immunopharmacology 1993b; 26: 197
   PubMedGoogle Scholar
• Gottlieb N. L. Comparative pharmacokinetics of parenteral and oral gold compounds. J. Rheumatol. 1982, suppl. 9: 99
   Google Scholar
• Hashimoto K., Whitehurst C. E., Matsubara T., Hirohata K., Lipsky P. E. Immimomodulatory effects of therapeutic gold compounds: gold sodium thiomalate inhibits the activity of T cell protein kinase C. J. Clin. Invest. 1992; 89: 1839
   PubMed Web of Science ®Google Scholar
• Hawkins C. J., Vaux D. L. Analysis of the role of bcl-2 in apoptosis. Immunol. Reviews 1994; 142: 127
   PubMed Web of Science ®Google Scholar
• Hearth-Holmes M., Holcombe R. F., Elder C., Wolf R. E. 2-chlorodeoxyadenosine (2-CdA) in patients wth systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1995; 38(No 9 (suppl.))S304
   Google Scholar
• Huang M. C., Ashmun R. A., Avery T. L., Kuehl M., Blakley R. L. Effects and cytotoxicity of 2-chloro-2′-deoxyadenosine and 2-bromo-2′-deoxyadenosine on cell growth, clonogenicity, DNA synthesis, and cell cycle kinetics. Cancer Res. 1986; 46: 2362
   PubMed Web of Science ®Google Scholar
• Lipsky P. E. Mechanisms of action of slow acting drugs in rheumatoid arthritis. Clin. Exp. Rheumatol. 1989; 3: 177
   Google Scholar
• Massarotti E. M., Liu N. Y., Mier J., Atkins M. B. Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am. J. Med. 1992; 92: 693
   PubMed Web of Science ®Google Scholar
• Moreland L. W., Sewell K. L., Trentham D. E., Bucy R. P., Sullivan W. F., Schrohenloher R. E., Shmerling R. H., Parker K. C., Swartz W. G., Woodworth G., Koopman W. J. Interleukin-2 diphtheria fusion protein (DAB 486IL-2) in refractory rheumatoid arthritis. Arthritis Rheum. 1995; 38: 1177
   PubMed Web of Science ®Google Scholar
• Mountz J. D., Wy J., Cheng J., Zhou T. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum. 1991; 37: 1415
   Google Scholar
• Muller-Laduer U., Kriegsman J., Gay R. F., Mountz J. D., Nishioka K., Talal N., Gay S. Upregulation of bcl-2 mRNA in synovium of patients with Rheumatoid Arthritis. Arthritis Rheum 1994; 37(No 9 (suppl))S163
   Google Scholar
• Nakayama K.-I., Nakayama K., Negishi I., Kuida K., Shinkai Y., Louie M. C., Fields L. E., Lucas P. J., Stewart V., Alt F. W., Loh D. Y. Disappearence of the lymphoid system in bcl-2 homozygous mutant himeric mice. Science 1993; 261: 1584
   PubMed Web of Science ®Google Scholar
• Panayi G. S., Lanchbury J. S., Kingsley G. H. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis (editorial). Arthritis Rheum. 1992; 35: 729
   PubMed Web of Science ®Google Scholar
• Panayiotidis P., Kanagasabai G., Jabbar S. A. B., Hoffbrand A. V. lnterleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukemia cells in vitro. Br. J. Haematol. 1993; 85: 439
   PubMed Web of Science ®Google Scholar
• Piro L. D., Carrera C. J., Beutler E., Carson D. A. Lasting remission in hairy cell leukemia-like induced by a single infusion of 2-chlorodeoxyadenosine. N Engl. J. Med. 1990; 322: 1117
   PubMed Web of Science ®Google Scholar
• Reed J. C., Tsujimoto Y., Alpers J. D., Crace C. M., Nowell P. Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science 1987; 236: 1295
   PubMed Web of Science ®Google Scholar
• Reed J. C. Bcl-2 family proteins and mechanisms of chemoresistance in lymphomas and leukemias. Adv Leukemia Lymphoma 1995; 5(No3)3
   Google Scholar
• Robertson L. E., Shubb S., Meyen R. E., Story M., Ford R., Hittelman W. N., Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′deoxyadenosine and 9-β-Darabinosyl-2-fluoroandenine. Blood 1992; 81: 143
   Web of Science ®Google Scholar
• Santana V. M., Hurwitz C. A., Blakley R. L., Crom W. R., Luo X., Roberts W. M., Ribeiro R., Mahmoud H., Krance R. A. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994; 84: 1237
   PubMed Web of Science ®Google Scholar
• Sipe J. C., Romine J. S., Koziol J. A. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9
   PubMed Web of Science ®Google Scholar
• Sfikakis P. P., Souliotis V., Panayotides P. P. Suppression of lnterleukin-2 and lnterleukin-2 receptor biosynthesis by gold compounds in in vitro activated human peripheral blood mononuclear cells. Arthritis Rheum. 1993; 36: 208
   PubMedGoogle Scholar
• Sfikakis P. P., Panayiotides P. Suppression of lnterleukin-2 and lnterleukin-2 receptor biosynthesis by gold compounds in in vitro activated human peripheral blood mononuclear cells. Letter Arthritis Rheum. 1994; 37: 147
   Google Scholar
• Sfikakis P. P., Souliotis V., Katsilambros N., Markakis K., Vaiopoulos G., Tsokos G. C., Panayotidis P. P. Down-regulation of Interleukin-2 and a-chain Interleukin-2 receptor biosynthesis by cisplatin in human peripheral lymphocytes. Clin Immunol. Immunopathol. 1996a; 79: 43
   PubMedGoogle Scholar
• Sfikakis P. P., Souliotis V., Akbar A. N., Katsilambros N., Hoffbrand V. A., Panayotides P. P. Regulation of bcl-2 and fas expression in primary activation of human peripheral lymphocytes is not sensitive to dexamethasone or cyclosporin-A. Human Immunol. 1996b; 50: 121
   PubMed Web of Science ®Google Scholar
• Strasser A., Harris A. W., Cory S. BCL-2 transgene inhibits T cell death and perturbs thymic self-sensorchip. Cell 1991a; 67: 889
   PubMed Web of Science ®Google Scholar
• Strasser A., Whittingham S., Vaux D. L., Bath M. L., Adams J. M., Cory S., Harris A. W. Enforced BCL-2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl. Acad. Sci. 1991b; 88: 8661
   PubMed Web of Science ®Google Scholar
• Tanghe A., Delforge A., Bernier M., Massy M., De Leeuw N., Bron D., Stryckmans P. Apoptosis of B-chronic lymphocytic leukemia (CLL) cells in presence of various agents and modulation by lnterleukin-4. Blood 1994; 84(Suppl 1 to No 10)451a
   Google Scholar
• Taniguchi T., Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993; 73: 5
   PubMed Web of Science ®Google Scholar
• Theofilopoulos A. N. The basis of autoimmunity: Part II Genetic predisposition. Immunol. Today 1995; 16: 150
   PubMedGoogle Scholar
• Ugai K., Ziff M., Lipsky P. E. Gold-induced changes in the morphology and functional capabilities of human monocytes. Arthritis Rheum. 1979; 22: 1352
   PubMedGoogle Scholar
• Wolf R. E., Hall V. C. Inhibition of in vitro proliferation response of cultured T lymphocytes to interleukin-2 by gold sodium thiomalate. Arthritis Rheum. 1988; 31: 176
   PubMed Web of Science ®Google Scholar